Zobrazeno 1 - 10
of 161
pro vyhledávání: '"Heiner Schäfer"'
Autor:
Dinara Baiskhanova, Heiner Schäfer
Publikováno v:
Antioxidants, Vol 13, Iss 6, p 696 (2024)
The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) represents the master regulator of the cellular antioxidant response and plays a critical role in tumorigenesis. This includes a preventive effect of Nrf2 on cell death throu
Externí odkaz:
https://doaj.org/article/9e528ead6aec4ec0a35e8ed8dd51b807
Autor:
Claudia Geismann, Charlotte Hauser, Frauke Grohmann, Christian Schneeweis, Nico Bölter, Jan-Paul Gundlach, Günter Schneider, Christoph Röcken, Christian Meinhardt, Heiner Schäfer, Stefan Schreiber, Alexander Arlt
Publikováno v:
Cell Death and Disease, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract The emergence of resistance to systemic therapies in pancreatic ductal adenocarcinoma (PDAC) is still a major obstacle in clinical practice. Both, constitutive and inducible NF-κB activity are known as key players in this context. To identi
Externí odkaz:
https://doaj.org/article/c49d5f0c0be94c26918207d7b67b5744
Autor:
Tina Daunke, Silje Beckinger, Sascha Rahn, Sandra Krüger, Steffen Heckl, Heiner Schäfer, Daniela Wesch, Christian Pilarsky, Markus Eckstein, Arndt Hartmann, Christoph Röcken, Anna Maxi Wandmacher, Susanne Sebens
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionImmune checkpoint inhibitors (ICI), e.g., targeting programmed cell death protein 1-ligand 1 (PD-L1) or its receptor PD-1, have markedly improved the therapy of many cancers but so far failed in pancreatic ductal adenocarcinoma (PDAC). Ma
Externí odkaz:
https://doaj.org/article/f2babd76fb144183893834bce80fb625
Autor:
Silje Beckinger, Tina Daunke, Leon Aldag, Sandra Krüger, Steffen Heckl, Daniela Wesch, Heiner Schäfer, Christoph Röcken, Sascha Rahn, Susanne Sebens
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionPancreatic ductal adenocarcinoma (PDAC) represents the 4th most common cause of cancer-related deaths in Western countries. Most patients are diagnosed at advanced stages, often already with metastases. The main site of metastasis is the
Externí odkaz:
https://doaj.org/article/817692eed56944a0ad4bfc2a431adf27
Autor:
Nourhane Ammar, Maya Hildebrandt, Claudia Geismann, Christian Röder, Timo Gemoll, Susanne Sebens, Ania Trauzold, Heiner Schäfer
Publikováno v:
Antioxidants, Vol 12, Iss 10, p 1818 (2023)
Metabolic compartmentalization of stroma-rich tumors, like pancreatic ductal adenocarcinoma (PDAC), greatly contributes to malignancy. This involves cancer cells importing lactate from the microenvironment (reverse Warburg cells) through monocarboxyl
Externí odkaz:
https://doaj.org/article/3f337b46b0c8422fa790dcd023bbceb6
Autor:
Anna Willms, Hella Schupp, Michelle Poelker, Alshaimaa Adawy, Jan Frederik Debus, Torsten Hartwig, Tim Krichel, Jürgen Fritsch, Steven Singh, Henning Walczak, Silvia von Karstedt, Heiner Schäfer, Anna Trauzold
Publikováno v:
Cell Death and Disease, Vol 12, Iss 8, Pp 1-12 (2021)
Abstract TNF-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAIL-R2) can induce apoptosis in cancer cells upon crosslinking by TRAIL. However, TRAIL-R2 is highly expressed by many cancers suggesting pro-tumor functions. Indeed, TRAIL/TRAIL-R2
Externí odkaz:
https://doaj.org/article/01faaca6a4584d9ebb8d543b9bdea437
Autor:
Steffen M. Heckl, Lukas Kercher, Samir Abdullazade, Carolin Schneider, Sandra Krüger, Hans-Michael Behrens, Susanne Sebens, Heiner Schäfer, Stefan Schreiber, Christoph Röcken
Publikováno v:
Cancers, Vol 13, Iss 19, p 4988 (2021)
Background: The proximity of pancreatic cancer (PDAC) to the physiological source of the growth promoting hormone insulin might be exploited by this highly malignant cancer entity. We investigated if (I) PDACs express the insulin receptor (IR) in can
Externí odkaz:
https://doaj.org/article/f0465fd89022440e8f93d77193d56cd5
Autor:
Steffen M. Heckl, Franziska Mau, Anke Senftleben, Tina Daunke, Silje Beckinger, Samir Abdullazade, Stefan Schreiber, Christoph Röcken, Susanne Sebens, Heiner Schäfer
Publikováno v:
Medical Sciences, Vol 9, Iss 3, p 48 (2021)
Type-2 diabetes (T2DM) is a risk factor for the development of pancreatic ductal adenocarcinoma (PDAC) and is characterized by insulin resistance and hyperinsulinemia. Besides the well-known growth-promoting activity of insulin or the other members o
Externí odkaz:
https://doaj.org/article/48b37b1f1d5045478226278418c337b9
Autor:
Lilli Otto, Sascha Rahn, Tina Daunke, Frederik Walter, Elsa Winter, Julia Luisa Möller, Stefan Rose-John, Daniela Wesch, Heiner Schäfer, Susanne Sebens
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 10, p 5086 (2021)
Pancreatic ductal adenocarcinoma (PDAC) is still one of the most aggressive solid malignancies with a poor prognosis. Obesity and type 2 diabetes mellitus (T2DM) are two major risk factors linked to the development and progression of PDAC, both often
Externí odkaz:
https://doaj.org/article/ddf822b0cf9e47cb90ed589c37475007
Autor:
Leontine Sandforth, Nourhane Ammar, Lisa Antonia Dinges, Christoph Röcken, Alexander Arlt, Susanne Sebens, Heiner Schäfer
Publikováno v:
Cancers, Vol 12, Iss 3, p 581 (2020)
Metabolite exchange between stromal and tumor cells or among tumor cells themselves accompanies metabolic reprogramming in cancer including pancreatic adenocarcinoma (PDAC). Some tumor cells import and utilize lactate for oxidative energy production
Externí odkaz:
https://doaj.org/article/a04e7ccd9c324a99b8f06a0b5722b775